These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8488954)

  • 61. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 62. Erythropoietin overview--1993.
    Nissenson AR
    Blood Purif; 1994; 12(1):6-13. PubMed ID: 7986477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients].
    Jacquot C; Berthelot JM; Chiappini-Judith D; Ferragu-Haguet M; Lefebvre A; Masselot JP; Moynot A; Frydman MO; Peterlongo F
    Nephrologie; 1990; 11(1):11-6. PubMed ID: 2374641
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation.
    Jaar B; Denis A; Viron B; Verdy E; Chamma F; Siohan P; Mignon F
    Am J Nephrol; 1997; 17(5):399-405. PubMed ID: 9382155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Trends in anemia management among US hemodialysis patients.
    Coladonato JA; Frankenfield DL; Reddan DN; Klassen PS; Szczech LA; Johnson CA; Owen WF
    J Am Soc Nephrol; 2002 May; 13(5):1288-95. PubMed ID: 11961017
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study.
    Klinkmann H; Wieczorek L; Scigalla P
    Artif Organs; 1993 Apr; 17(4):219-25. PubMed ID: 8498900
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 69. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mortality risk in hemodialysis patients according to anemia control and erythropoietin dosing.
    Santos PR; Melo AD; Lima MM; Negreiros IM; Miranda JS; Pontes LS; Rabelo GM; Viana AC; Alexandrino MT; Barros FA; Neto BR; Brito AA; Da Silva Costa A
    Hemodial Int; 2011 Oct; 15(4):493-500. PubMed ID: 22111817
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis.
    Nakao T; Matsumoto H; Okada T; Han M; Hidaka H; Yoshino M; Shino T; Yamada C; Nagaoka Y
    Intern Med; 1998 Oct; 37(10):826-30. PubMed ID: 9840702
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease.
    Korbet SM
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):9-15. PubMed ID: 2648520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oral iron absorption in hemodialysis patients treated with erythropoietin.
    Donnelly SM; Posen GA; Ali MA
    Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
    Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
    Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
    [No Abstract]   [Full Text] [Related]  

  • 78. Reactivity of patients with maintenance hemodialysis to erythropoietin in the treatment of renal anemia.
    Hu JP; Cheng X; Xu XF; Yu GJ; Luo F; Zhang GS; Yang N; Shen P; Yan XY
    J Biol Regul Homeost Agents; 2016; 30(2):535-40. PubMed ID: 27358145
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis].
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Solarska K
    Pol Arch Med Wewn; 1991 Jun; 85(6):352-5. PubMed ID: 1716757
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
    Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
    Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.